InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and efficacy of ICP-488 in patients with moderate-to-severe psoriasis.
ICP-488 is a potent and selective TYK2 allosteric inhibitor developed for the treatment of psoriasis and other autoimmune diseases. By blocking the signal transduction of inflammatory cytokines, such as IL-23, IL-12, and type 1 IFN, ICP-488 inhibits the pathological process of autoimmune and inflammatory diseases.
Dr. Jasmine Cui, the co-founder, Chairwoman, and CEO of InnoCare, expressed that there is a significant unmet need for effective treatments for autoimmune diseases like psoriasis. In addition